
Sign up to save your podcasts
Or


The JournalFeed podcast for the week of June 22-26, 2026.
These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.
Thursday’s Spoon Feed:
Tirofiban resulted in greater 90-day excellent neurological outcomes vs. placebo in patients with no medium or large vessel occlusion (LVO) who were not improving with with tenecteplase (TNK), NNT = 9.
Friday’s Spoon Feed:
Dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin vs. placebo in patients with stroke treated with thrombolysis resulted in better 90-day excellent neurological outcome, NNT = 15, without a significant increase in symptomatic intracranial hemorrhage (sICH).
By Nick Zelt5
1919 ratings
The JournalFeed podcast for the week of June 22-26, 2026.
These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.
Thursday’s Spoon Feed:
Tirofiban resulted in greater 90-day excellent neurological outcomes vs. placebo in patients with no medium or large vessel occlusion (LVO) who were not improving with with tenecteplase (TNK), NNT = 9.
Friday’s Spoon Feed:
Dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin vs. placebo in patients with stroke treated with thrombolysis resulted in better 90-day excellent neurological outcome, NNT = 15, without a significant increase in symptomatic intracranial hemorrhage (sICH).

43,926 Listeners

32,106 Listeners

63,941 Listeners

1,868 Listeners

545 Listeners

275 Listeners

508 Listeners

259 Listeners

162 Listeners

59,108 Listeners

87,542 Listeners

112,063 Listeners

269 Listeners

56,553 Listeners

270 Listeners